JP2010523714A5 - - Google Patents

Download PDF

Info

Publication number
JP2010523714A5
JP2010523714A5 JP2010503249A JP2010503249A JP2010523714A5 JP 2010523714 A5 JP2010523714 A5 JP 2010523714A5 JP 2010503249 A JP2010503249 A JP 2010503249A JP 2010503249 A JP2010503249 A JP 2010503249A JP 2010523714 A5 JP2010523714 A5 JP 2010523714A5
Authority
JP
Japan
Prior art keywords
composition
melatonin
individual
ketone bodies
ketone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2010503249A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010523714A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2008/060100 external-priority patent/WO2008128095A1/en
Publication of JP2010523714A publication Critical patent/JP2010523714A/ja
Publication of JP2010523714A5 publication Critical patent/JP2010523714A5/ja
Pending legal-status Critical Current

Links

JP2010503249A 2007-04-12 2008-04-11 虚血/再灌流保護組成物および使用法 Pending JP2010523714A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US91146007P 2007-04-12 2007-04-12
US2632108P 2008-02-05 2008-02-05
PCT/US2008/060100 WO2008128095A1 (en) 2007-04-12 2008-04-11 Ischemia/reperfusion protection compositions and methods of using

Publications (2)

Publication Number Publication Date
JP2010523714A JP2010523714A (ja) 2010-07-15
JP2010523714A5 true JP2010523714A5 (https=) 2012-04-26

Family

ID=42269849

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010503249A Pending JP2010523714A (ja) 2007-04-12 2008-04-11 虚血/再灌流保護組成物および使用法

Country Status (12)

Country Link
US (4) US9186340B2 (https=)
EP (1) EP2146711A4 (https=)
JP (1) JP2010523714A (https=)
KR (1) KR20100016456A (https=)
CN (1) CN101677996A (https=)
AU (1) AU2008240211A1 (https=)
BR (1) BRPI0811052A2 (https=)
CA (1) CA2684213A1 (https=)
IL (1) IL201406A0 (https=)
MX (1) MX2009011002A (https=)
RU (1) RU2459624C2 (https=)
WO (1) WO2008128095A1 (https=)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0811052A2 (pt) * 2007-04-12 2015-01-27 Univ Minnesota Composições de proteção de isquemia/reperfusão e métodos de uso.
SG10201908576VA (en) * 2010-04-08 2019-10-30 Hospital For Sick Children Use of remote ischemic conditioning for traumatic injury
NL2004569C2 (en) * 2010-04-16 2011-10-18 Angteq B V Compounds for prevention of cell injury.
WO2012103411A2 (en) 2011-01-28 2012-08-02 Zx Pharma, Llc Controlled-release melatonin composition and related methods
US9532952B2 (en) 2011-01-28 2017-01-03 Physician's Seal, LLC Controlled-release compositions of melatonin combined with sedative and/or analgesic ingredients
US10531655B2 (en) 2011-12-02 2020-01-14 The Regents Of The University Of California Reperfusion protection solution and uses thereof
RU2488388C1 (ru) 2012-05-24 2013-07-27 Ооо "Валента Интеллект" Фармацевтическая композиция для профилактики и лечения психических, поведенческих, когнитивных расстройств
ITMI20120913A1 (it) * 2012-05-28 2013-11-29 Nicoletta Maxia Uso della n-acetil-5-metossitriptamina o suoi analoghi per favorire il meccanismo di impianto dell' embrione, e relative composizioni e mezzi di coltura
UA107653U (uk) 2012-10-01 2016-06-24 Общєство С Огранічєнной Отвєтствєнностью "Валєнта-Інтєллєкт" Композиція лікарських засобів для лікування та профілактики поведінкових, психічних та когнітивних розладів
KR102499654B1 (ko) * 2013-03-19 2023-02-13 유니버시티 오브 사우스 플로리다 상승되고 지속되는 케톤증을 생성하기 위한 조성물 및 방법
CN104208059A (zh) * 2014-09-05 2014-12-17 中国医学科学院北京协和医院 褪黑素在制备保护吸烟引起血管损伤药物中的应用
US10596131B2 (en) 2017-11-22 2020-03-24 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use
US10596130B2 (en) 2017-12-19 2020-03-24 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the S-enantiomer and methods of use
US10973786B2 (en) 2016-03-11 2021-04-13 Axcess Global Sciences, Llc R-beta-hydroxybutyrate, S-beta-hydroxybutyrate, and RS-beta-hydroxybutyrate mixed salt compositions
US10245243B1 (en) 2017-12-19 2019-04-02 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the S-enantiomer and methods of use
US11185518B2 (en) 2017-12-19 2021-11-30 Axcess Global Sciences, Llc S-beta-hydroxybutyrate compounds and compositions enriched with S-enantiomer
US10245242B1 (en) 2017-11-22 2019-04-02 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use
US10973792B2 (en) 2019-02-13 2021-04-13 Axcess Global Sciences, Llc Racemic beta-hydroxybutyrate mixed salt-acid compositions and methods of use
US10292952B2 (en) 2016-03-11 2019-05-21 Axcess Global Sciences, Llc Mixed salt compositions for maintaining or restoring electrolyte balance while producing elevated and sustained ketosis
US10736861B2 (en) 2016-03-11 2020-08-11 Axcess Global Sciences, Llc Mixed salt compositions for producing elevated and sustained ketosis
US10596129B2 (en) 2017-11-22 2020-03-24 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use
US11241403B2 (en) 2016-03-11 2022-02-08 Axcess Global Sciences, Llc Beta-hydroxybutyrate mixed salt compositions and methods of use
US11103470B2 (en) 2017-11-22 2021-08-31 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use
US20170266147A1 (en) * 2016-03-18 2017-09-21 Csilla Ari D'Agostino Methods of increasing latency of anesthetic induction using ketone supplementation
WO2017165443A1 (en) * 2016-03-21 2017-09-28 Csilla Ari D'agostino Methods of improving motor function using ketone supplementation
US12533346B2 (en) 2016-04-19 2026-01-27 Axcess Global Sciences, Llc Administration of berberine metabolites
US12109182B2 (en) 2016-04-19 2024-10-08 Axcess Global Sciences, Llc Administration of R-beta-hydroxybutyrate and related compounds in humans
US12599579B2 (en) 2016-04-19 2026-04-14 Axcess Global Sciences, Llc Compositions and compounds containing ketone bodies and/or ketone body precursors and one or more amino acids
US11202769B2 (en) 2017-11-22 2021-12-21 Axcess Global Sciences, Llc Ketone body esters of s-beta-hydroxybutyrate and/or s-1,3-butanediol for modifying metabolic function
US20230346721A1 (en) 2018-04-18 2023-11-02 Axcess Global Sciences, Llc Beta-hydroxybutyric acid compositions and methods for delivery of ketone bodies
US12521378B2 (en) 2016-04-19 2026-01-13 Axcess Global Sciences, Llc Administration of R-beta-hydroxybutyrate salt blend and related compounds in humans
US10925843B2 (en) 2018-04-18 2021-02-23 Axcess Global Sciences, Llc Compositions and methods for keto stacking with beta-hydroxybutyrate and acetoacetate
US12496283B2 (en) 2016-04-19 2025-12-16 Axcess Global Sciences, Llc Administration of R-beta-hydroxybutyrate and related compounds in humans
US11944598B2 (en) 2017-12-19 2024-04-02 Axcess Global Sciences, Llc Compositions containing s-beta-hydroxybutyrate or non-racemic mixtures enriched with the s-enatiomer
US12329734B2 (en) 2017-12-19 2025-06-17 Axcess Global Sciences, Llc Use of S-beta-hydroxybutyrate compounds for induction and maintenance of flow
US11806324B2 (en) 2018-04-18 2023-11-07 Axcess Global Sciences, Llc Beta-hydroxybutyric acid compositions and methods for oral delivery of ketone bodies
CN109890381A (zh) * 2016-09-12 2019-06-14 南佛罗里达大学 酮改善神经再生
US10307398B2 (en) 2016-09-20 2019-06-04 Regents Of The University Of Minnesota Resuscitation composition and methods of making and using
US9925164B1 (en) 2017-01-12 2018-03-27 Neuroenergy Ventures, Inc. Glyceryl 3-hydroxybutyrates for traumatic brain injury
WO2018167273A1 (en) * 2017-03-16 2018-09-20 Repoceuticals Aps Compositions for retarding the decomposition of melatonin in solution
EP3609484A4 (en) * 2017-04-12 2020-12-16 Cavaleri, Franco BUTYRATE AND BETA HYDROXYBUTYRATE COMPOSITIONS AND METHODS FOR THEIR USE
JP7136807B2 (ja) 2017-04-17 2022-09-13 ザ・ユニバーシティ・オブ・シカゴ ヒトの健康及び疾患の治療用途向けの短鎖脂肪酸の腸への送達用ポリマー材料
US10179095B2 (en) * 2017-06-07 2019-01-15 Dr. Raymond Laboratories Autophage activating resveratrol topical composition for skin improvement and treatment
US12090129B2 (en) 2017-11-22 2024-09-17 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use
US11241401B2 (en) 2020-02-06 2022-02-08 Axcess Global Sciences, Llc Enantiomerically pure r-beta-hydroxybutyrate mixed salt-acid compositions
US11129802B2 (en) 2018-08-27 2021-09-28 Axcess Global Sciences, Llc Compositions and methods for delivering cannabidiol and ketone bodies
US11419836B2 (en) 2019-02-13 2022-08-23 Axcess Global Sciences, Llc Racemic and near racemic beta-hydroxybutyrate mixed salt-acid compositions
US10512615B1 (en) 2018-08-27 2019-12-24 Axcess Global Sciences, Llc Compositions and methods for delivering cannabidiol and ketone bodies
US10980772B2 (en) 2018-08-27 2021-04-20 Axcess Global Sciences, Llc Compositions and methods for delivering tetrahydrocannabinol and ketone bodies
AU2018260927B1 (en) * 2018-05-25 2019-02-21 Graham Sherard Baldwin Methods and compositions for inhibiting a noxious insult
BR112020023132A2 (pt) * 2018-06-21 2021-02-09 Société des Produits Nestlé S.A. composições e métodos que usam um precursor de nicotinamida adenina dinucleotídeo (nad+) e pelo menos uma cetona ou um precursor de cetona
JP2020125254A (ja) * 2019-02-04 2020-08-20 株式会社協和 化粧料、紫外線に対する細胞保護剤、光老化防止剤
US12472200B2 (en) 2019-05-15 2025-11-18 Axcess Global Sciences, Llc Autobiotic compositions and method for promoting healthy gut microbiome
PL3976021T3 (pl) * 2019-05-30 2025-07-21 Neuroenergy Ventures, Inc. Tri(beta-hydroksymaślan) glicerolu do zastosowania w leczeniu i zapobieganiu przemijającym atakom niedokrwiennym neuronów
US12167993B2 (en) 2019-06-21 2024-12-17 Axcess Global Sciences, Llc Non-vasoconstricting energy-promoting compositions containing ketone bodies
US11950616B2 (en) 2019-06-21 2024-04-09 Axcess Global Sciences, Llc Non-vasoconstricting energy-promoting compositions containing ketone bodies
US11969430B1 (en) 2023-03-10 2024-04-30 Axcess Global Sciences, Llc Compositions containing paraxanthine and beta-hydroxybutyrate or precursor for increasing neurological and physiological performance
US11033553B2 (en) 2019-06-21 2021-06-15 Axcess Global Sciences, Llc Non-vasoconstricting energy-promoting compositions containing ketone bodies
US12186297B2 (en) 2020-08-26 2025-01-07 Axcess Global Sciences, Llc Compositions and methods for increasing lean-to-fat mass ratio
US20230277484A1 (en) * 2022-03-04 2023-09-07 Guardian Biosciences, LLC Compositions and methods to promote brain health
CN119345192B (zh) * 2024-11-27 2025-10-28 广西医科大学 N-乙酰血清素在防治糖尿病中的应用

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4298601A (en) 1972-03-06 1981-11-03 Technutra, S.A. Method and formulations for the treatment of obesity
FR2490631A1 (fr) 1980-09-24 1982-03-26 Roussel Uclaf Nouvelle composition lipidique utilisable en dietetique, reanimation et therapeutique
US5141674A (en) 1984-03-08 1992-08-25 Phares Pharmaceutical Research N.V. Methods of preparing pro-liposome dispersions and aerosols
ATE82500T1 (de) 1984-06-22 1992-12-15 Richard L Veech Elektrolytloesungen und deren (in vivo) verwendung.
DE3581407D1 (de) * 1985-09-06 1991-02-21 Nestle Sa Bewahrung lebender gewebe.
US5719119A (en) 1985-12-18 1998-02-17 British Technology Group, Ltd. Parenteral nutrition therapy with amino acids
JPS63502274A (ja) 1985-12-18 1988-09-01 ビ−チ,リチヤ−ド エル L↓−乳酸および/またはピルビン酸アニオンを用いた流体式治療法
US5049388A (en) 1986-11-06 1991-09-17 Research Development Foundation Small particle aerosol liposome and liposome-drug combinations for medical use
US5120763A (en) 1986-11-26 1992-06-09 Bar Ilan University Physiologically active and nutritional composition
WO1991002535A1 (en) 1989-08-11 1991-03-07 Basil, Inc. Cancer prevention composition and method
US5257985A (en) 1989-12-04 1993-11-02 Richard Puhl Multi-chamber intravenous bag apparatus
US5098409A (en) 1991-01-04 1992-03-24 Massachusetts Institute Of Technology Intravenous bag and monitoring method
US5654266A (en) * 1992-02-10 1997-08-05 Chen; Chung-Ho Composition for tissues to sustain viability and biological functions in surgery and storage
US6582728B1 (en) 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
US5405333A (en) * 1992-12-28 1995-04-11 Richmond; Frank M. Liquid medicament bag with needleless connector fitting using boat assembly
US7083572B2 (en) 1993-11-30 2006-08-01 Bristol-Myers Squibb Medical Imaging, Inc. Therapeutic delivery systems
US5814663A (en) 1994-08-29 1998-09-29 Wisconsin Alumni Research Foundation Method for maintaining an existing level of body fat
JP4598203B2 (ja) 1995-12-01 2010-12-15 ビーティージー・インターナショナル・リミテッド 脳機能改善剤
US5700828A (en) * 1995-12-07 1997-12-23 Life Resuscitation Technologies, Inc. Treatment or prevention of anoxic or ischemic brain injury with melatonin-containing compositions
CA2283642C (en) 1997-03-17 2012-05-15 Btg International Limited Therapeutic compositions
US6316038B1 (en) 1997-03-17 2001-11-13 Btg International Limited Therapeutic compositions
US6323237B1 (en) 1997-03-17 2001-11-27 Btg International Limited Therapeutic compositions
US6262111B1 (en) 1997-05-21 2001-07-17 Sloan-Kettering Institute For Cancer Research Method for increasing the concentration of ascorbic acid in brain tissues of a subject
US5853388A (en) 1997-08-21 1998-12-29 Semel; David Intravenous bag with separate compartment
US6107349A (en) 1998-04-16 2000-08-22 Mantynen; Philip R. Method and composition for treating psoriasis
US6353015B1 (en) 1998-08-26 2002-03-05 St. Elizabeth's Medical Center Method of treating neurodegenerative disorders
WO2000015216A1 (en) 1998-09-15 2000-03-23 Btg International Limited Therapeutic compositions (ii)
US6232354B1 (en) * 1999-01-25 2001-05-15 Seng C. Tan Microcellular polymer foams and method for their production
DE60038100T2 (de) 1999-02-26 2009-02-12 Johnson & Johnson Consumer Companies, Inc. Bioadhäsive antibakterielle wundheilungszusammensetzungen
US20010051652A1 (en) * 1999-04-28 2001-12-13 Ajinomoto Co., Inc. Method of treating paralysis of the extremities caused by cerebral infarction
US6890896B1 (en) 1999-11-18 2005-05-10 Ceremedix, Inc. Compositions and methods for counteracting effects of reactive oxygen species and free radicals
US6579852B2 (en) 2000-01-14 2003-06-17 Genset S.A. OBG3 globular head and uses thereof for decreasing body mass
US6391345B1 (en) 2000-05-12 2002-05-21 Tim Heeg Cranberry seed oil, cranberry seed flour and a method for making
DE10028837A1 (de) 2000-06-15 2001-12-20 Roche Diagnostics Gmbh Verfahren zum Nachweis von Influenza A/B-Viren
US20020077317A1 (en) 2000-12-15 2002-06-20 Das Undurti Narasimha Method of potentating the action of 2-methoxyoestradiol, statins and C-peptide of proinsulin
US20050129783A1 (en) 2001-04-19 2005-06-16 Mccleary Edward L. Composition and method for treatment of neurophysiological conditions and maintenance of neurophysiological health
WO2004047871A2 (en) 2002-11-26 2004-06-10 Nobex Corporation Modified naturetic compounds, conjugates, and uses thereof
EP1587510A4 (en) 2003-01-31 2007-08-08 Univ Hong Kong METHOD OF TREATING ISCHEMIC BUST WITH MELATONIN
IL155666A (en) * 2003-04-29 2013-12-31 Neurim Pharma 1991 Insomnia treatment
US6919483B2 (en) 2003-05-23 2005-07-19 Mediquest Therapeutics, Inc. Immunomodulation with novel pharmaceutical compositions
EP1648952B1 (en) 2003-06-03 2018-03-07 THE UNITED STATES GOVERNMENT as represented by THE DEPARTMENT OF HEALTH AND HUMAN SERVICES Nutritional supplements and therapeutic compositions comprising (r)-3-hydroxybutyrate derivatives
GB0410266D0 (en) 2004-05-07 2004-06-09 Ketocytonyx Inc Treatment of apoptosis
GB0420856D0 (en) 2004-09-20 2004-10-20 Ketocytonyx Inc Cns modulators
EP1778213B1 (en) 2004-07-16 2017-04-05 BTG International Limited A method for the synthesis of oligomeric compounds
WO2006020179A2 (en) 2004-07-20 2006-02-23 Ketocytonyx Inc. Oligomeric ketone compounds
WO2006012490A2 (en) 2004-07-23 2006-02-02 Ketocytonyx Inc. Ketogenic saccharides
US20070281892A1 (en) 2004-09-21 2007-12-06 Martin Keith F Dopaminergic Mimetics
WO2006098767A2 (en) 2004-09-21 2006-09-21 Ketocytonyx Inc. Treatment of adhd
GB0427145D0 (en) 2004-12-10 2005-01-12 Ketocytonyx Inc Compositions for use in surgery
BRPI0811052A2 (pt) 2007-04-12 2015-01-27 Univ Minnesota Composições de proteção de isquemia/reperfusão e métodos de uso.

Similar Documents

Publication Publication Date Title
JP2010523714A5 (https=)
RU2009141713A (ru) Защитные композиции от ишемии/реперфузии и способы применения
JP2019515908A5 (https=)
CN103167877A (zh) 包含谷胱甘肽还原酶和氧化型谷胱甘肽的组合物,以及其治疗用途
JP2015524444A5 (https=)
JP2011528333A5 (https=)
Smith et al. Therapeutic drug monitoring when using cefepime in continuous renal replacement therapy: seizures associated with cefepime
CA2393437A1 (en) Exo-s-mecamylamine formulation and use in treatment
JP2011225596A5 (https=)
ES2971959T3 (es) Terlipresina para el tratamiento de la ascitis debida a cirrosis hepática administrada como una infusión continua
ES2704229T3 (es) Agonistas selectivos del receptor AT2 para su uso en el tratamiento de la caquexia
JP2010511596A5 (https=)
RU2018121615A (ru) Модуляторы активности комплемента
WO2007087241A3 (en) Treatment of ischemic disease using thrombopoietin
JP2012525358A5 (https=)
WO2005065429B1 (en) Composition and method for treatment of hepatic encephalopathy
Goldschmidt et al. Compound cardiac toxicity of oral erythromycin and verapamil
JP2008520681A5 (https=)
JP2012526099A5 (https=)
JP2006502231A5 (https=)
JP2009504668A5 (https=)
CN101491527A (zh) 四氢嘧啶在制备治疗肝炎或肝硬化药物中的应用
CA2482687A1 (en) Treatment of mesothelioma
JP2008526816A5 (https=)
Hatori et al. Beneficial effects of coronary venous retroinfusion but not left atrial administration of superoxide dismutase on myocardial necrosis in pigs